Expression and clinical significance of cyclooxygenase-2 and microRNA-143 in osteosarcoma
- Authors:
- Yongchao Fang
- Zhiqiang Zhang
- Qiang Wang
- Jianning Zhao
View Affiliations
Affiliations: Department of Orthopedic Surgery, Jinling Hospital, Southern Medical University, Nanjing, Jiangsu 210002, P.R. China
- Published online on: April 14, 2015 https://doi.org/10.3892/etm.2015.2420
-
Pages:
2374-2378
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of the present study was to investigate the expression profiles of cyclooxygenase (COX)-2 and microRNA (miRNA)-143 in the tumor tissue and blood samples of patients with osteosarcoma, and their involvement in the disease pathogenesis. Tumor tissue and blood samples were obtained from 46 patients with osteosarcoma (stages I‑III). Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analyses were performed to detect the mRNA and protein expression of COX‑2, respectively, in these samples. The expression of miRNA‑143 in the tumor tissue and blood samples was assessed using RT‑qPCR. The results showed that, compared with the normal control subjects, the mRNA and protein expression levels of COX‑2 in the tumor tissue and blood samples of patients with osteosarcoma were increased. Among the patients with osteosarcoma, increases in the COX‑2 mRNA and protein levels were observed with progressing disease severity (from stage I to stage III), suggesting the involvement of COX‑2 in the disease pathogenesis. By contrast, the expression of miRNA‑143 decreased as the disease progressed, which was the opposite trend to the COX‑2 expression, indicating that miRNA‑143 and COX‑2 may play different roles in the disease pathogenesis. In conclusion, COX‑2 expression in the tumor tissue and blood samples of patients with osteosarcoma increases significantly along with the degree of tumor malignancy, and this is accompanied by a decreased expression of miRNA-143; therefore, a negative correlation between COX-2 and miRNA-143 may exist in the progression of osteosarcoma.
View References
|
1
|
Lei P, Xie J, Wang L, Yang X, Dai Z and Hu
Y: microRNA-145 inhibits osteosarcoma cell proliferation and
invasion by targeting ROCK1. Mol Med Rep. 10:155–160.
2014.PubMed/NCBI
|
|
2
|
Clark JC, Dass CR and Choong PF: A review
of clinical and molecular prognostic factors in osteosarcoma. J
Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kansara M and Thomas DM: Molecular
pathogenesis of osteosarcoma. DNA Cell Biol. 26:1–18. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cai ZD and Li GD: Ezrin protein: Novel hot
point of research on mechanism of neoplasm metastasis. Zhonghua
Zhong Liu Za Zhi. 6:3223252005.(In Chinese).
|
|
5
|
Gorlick R and Khanna C: Osteosarcoma. J
Bone Miner Res. 25:683–691. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ottaviani G and Jaffe N: The etiology of
osteosarcoma. Cancer Treat Res. 152:15–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kansara M, Leong HS, Lin DM, et al: Immune
response to RB1-regulated senescence limits radiation-induced
osteosarcoma formation. J Clin Invest. 123:5351–5360. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou X, Jing J, Peng J, et al: Expression
and clinical significance of galectin-3 in osteosarcoma. Gene.
546:403–407. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu X, Cai M, Ji F and Lou LM: The impact
of COX-2 on invasion of osteosarcoma cell and its mechanism of
regulation. Cancer Cell Int. 14:272014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu XL, Cheng B, Li PY, et al: MicroRNA-143
suppresses gastric cancer cell growth and induces apoptosis by
targeting COX-2. World J Gastroenterol. 19:7758–7765. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pham H, Rodriguez CE, Donald GW, et al:
miR-143 decreases COX-2 mRNA stability and expression in pancreatic
cancer cells. Biochem Biophys Res Commun. 439:6–11. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song T, Zhang X, Wang C, et al: Expression
of miR-143 reduces growth and migration of human bladder carcinoma
cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev.
12:929–933. 2011.PubMed/NCBI
|
|
13
|
Yamasaki L: Role of RB tumor suppressor in
cancer. Cancer Treat Res. 115:209–239. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jaffe N: Osteosarcoma. Pediatr Rev.
12:333–343. 1991.PubMed/NCBI
|
|
15
|
Alhouayek M and Muccioli GG: COX-2-derived
endocannabinoid metabolites as novel inflammatory mediators. Trends
Pharmacol Sci. 35:284–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang L, Wang Z, Li J, et al: NFATc1
activation promotes the invasion of U251 human glioblastoma
multiforme cells through COX-2. Int J Mol Med. Mar 4–2015.(Epub
ahead of print). doi. View Article : Google Scholar
|
|
17
|
Wu K, Fukuda K, Xing F, et al: Roles of
the cyclooxygenase 2-matrix metalloproteinase 1 pathway in brain
metastasis of breast cancer. J Biol Chem. Feb 17–2015.(Epub ahead
of print). pii: jbc.M114.602185. View Article : Google Scholar
|
|
18
|
Toujas L, Delcros J G, Diez E, et al:
Human monocyte-derived macrophages and dendritic cells are
comparably effective in vitro in presenting HLA class I-restricted
exogenous peptides. Immunol. 91:635–642. 1997. View Article : Google Scholar
|
